Johnson & Johnson

J&J Bispecific Duo Cuts PSA 50%+ in 73% of Prostate Cancer Patients

Image
J&J Bispecific Duo Cuts PSA 50%+ in 73% of Prostate Cancer Patients

New Brunswick, N.J. – November 08, 2026 -- Johnson & Johnson reported that 73% of patients (11 of 15) treated with its pasritamig and JNJ-9401 bispecific antibody combination achieved PSA reductions of at least 50% in a first-in-human Phase 1 study in metastatic castration-resistant prostate cancer (mCRPC). Seven of the 15 patients (47%) reached reductions of at least 90%. The data were presented in a late-breaking oral session at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting (Abstract #1175).

Dual-antigen regimen targets KLK2 and PSMA with complementary T-cell signals

The combination is the first dual-tumor-antigen-targeted bispecific regimen clinically evaluated in prostate cancer. Pasritamig, a first-in-class KLK2xCD3 bispecific, directs T cells toward prostate cancer cells. JNJ-9401, a PSMAxCD28 costimulatory bispecific, adds a second signal meant to strengthen and sustain T-cell activity.

J&J Data Ranks Mouth Dryness Top Sjögren's Priority for Nipocalimab

Image
J&J Data Ranks Mouth Dryness Top Sjögren's Priority for Nipocalimab

NEW BRUNSWICK, N.J. – November 07, 2026 -- Johnson & Johnson reported that 96% of Sjögren's disease patients interviewed after its Phase 2 DAHLIAS study cited mouth dryness as a symptom, making it both the most frequent complaint and the improvement patients prioritized most. The company will present the findings among 23 nipocalimab abstracts at the American College of Rheumatology (ACR) Convergence 2026.

Four core symptoms reported by more than 70% of interviewed patients

Besides mouth dryness (96%), patients most often reported fatigue (92%), eye dryness (90%) and joint pain (73%). Among women, 49% reported vaginal dryness. Patients said they saw improvements across many of these symptoms during the treatment phase.

Sjögren's disease is a chronic, systemic, autoantibody-driven condition affecting approximately four million people worldwide. It is nine times more common in women than in men.

FDA Grants Accelerated Approval to J&J's Subcutaneous RYBREVANT FASPRO in HNSCC

Image
FDA Grants Accelerated Approval to J&J's Subcutaneous RYBREVANT FASPRO in HNSCC

SAN DIEGO – November 06, 2026 -- The U.S. Food and Drug Administration granted Johnson & Johnson accelerated approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), a subcutaneous therapy co-formulated with Halozyme's ENHANZE technology, as a single agent for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), Halozyme Therapeutics (Nasdaq: HALO) announced.

FDA clears first dual-targeted therapy for post-chemotherapy, post-immunotherapy HNSCC

The indication covers adults whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. It excludes patients with HPV-associated oropharyngeal squamous cell carcinoma.

The approval is the first for a dual-targeted therapy in this setting. RYBREVANT FASPRO simultaneously targets epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), extending the product's dual-targeted profile beyond lung cancer.

FDA Approves J&J's Rybrevant Faspro for Head and Neck Cancer

Image
FDA Approves J&J's Rybrevant Faspro for Head and Neck Cancer

NEW BRUNSWICK, N.J. – November 06, 2026 -- The U.S. Food and Drug Administration has granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), backed by a confirmed 42 percent overall response rate in a 102-patient cohort.

Approval covers post-platinum, post-immunotherapy patients and excludes HPV-associated oropharyngeal disease

The subcutaneous single-agent therapy is cleared for adults whose disease progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The indication excludes patients with HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). J&J says it is the first dual-targeted therapy approved in this setting, hitting both EGFR and MET, and describes it as the first advance in second-line treatment of the disease in a decade.

Ophthalmic Equipment Market to Hit USD 30.5B by 2031

Image
Ophthalmic Equipment Market to Hit USD 30.5B by 2031

Sheridan, Wyoming – November 04, 2026 -- The global ophthalmic equipment market is valued at USD 21.2 billion in 2026 and will reach USD 30.5 billion by 2031, a 7.5% CAGR over 2026-2031, according to a new study by Wissen Research.

Untreated vision loss drives procurement toward two device tiers

The World Health Organization reported in February 2026 that at least 2.2 billion people have a near or distance vision impairment, and that at least 1 billion of those cases could have been treated. Cataracts affect more than 94 million people, and nearly half of those facing cataract-related blindness still lack access to surgery. Global cataract surgical coverage rose by about 15% over two decades, but WHO projects growth of only 8.4% in the current decade.

Wissen finds demand splitting in two: more capable surgical and imaging platforms in hospitals, and lower-cost portable and AI-assisted devices for patients far from specialist eye centres.

BioFuture 2026 Gathers 100+ Speakers to Tackle Biopharma AI, Funding, Policy

New York City – – September 29, 2026 -- Demy-Colton has released the agenda for BioFuture 2026, a two-day conference set for October 27–28 at Cure, 345 Park Avenue South, drawing more than 100 speakers and over 50 presenting companies from biopharma, investment, technology and policy sectors.

Conference agenda spans AI, oncology, biotech financing and global drug development

Speakers include representatives from Johnson & Johnson, Regeneron Pharmaceuticals, Schrödinger, Piper Sandler and Mizuho Securities. Sponsors backing the event include Regeneron Pharmaceuticals, Russo Partners, WuXi AppTec, Blue Matter, Cure, Evotec, Ipsen, Thermo Fisher Scientific, Big4Bio, HMA Consulting, Withum and Hogan Lovells Cadwalader.

J&J's CARVYKTI Shows 50% Five-Year Remission Rate in Early-Line Myeloma

Image
J&J's CARVYKTI Shows 50% Five-Year Remission Rate in Early-Line Myeloma

Raritan, N.J. – September 25, 2026 -- Half of patients with early-line relapsed or refractory multiple myeloma treated with a single infusion of Johnson & Johnson's CARVYKTI® (ciltacabtagene autoleucel) remained alive and progression-free for at least five years without maintenance therapy, according to new long-term data from the Phase 2 CARTITUDE-2 study.

Half of patients reach five-year progression-free survival without maintenance

In the initial subgroup of cohort A (N=20), 10 of 20 patients treated with a single CARVYKTI® infusion remained progression-free at a median follow-up of 60.7 months. Median progression-free survival reached 60.5 months, and the results were presented at the International Myeloma Society Annual Meeting (Abstract #PA-288). Cohort A enrolled patients who had received one to three prior lines of therapy, were exposed to a proteasome inhibitor, and were refractory to lenalidomide.

RYBREVANT Combo Extends Survival to 34.3 Months in Lung Cancer Trial

Image
RYBREVANT Combo Extends Survival to 34.3 Months in Lung Cancer Trial

Seoul – September 17, 2026 -- Johnson & Johnson reported that its RYBREVANT (amivantamab-vmjw) plus chemotherapy combination extended median overall survival to 34.3 months in patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer, compared with 27.9 months for chemotherapy alone, according to final data from the Phase 3 PAPILLON study.

Combination therapy nearly doubles historical survival benchmarks

The result marks the longest reported median overall survival for this patient population, which has historically faced a five-year survival rate of just 8 percent and a median overall survival ranging from 16 to 24 months. EGFR exon 20 insertion mutations account for approximately 12 percent of all EGFR mutations and have proven difficult to treat with existing targeted therapies.